bioAffinity Technologies Reports Third Quarter 2026 Financial Results
bioAffinity Technologies announced its financial results for the third quarter of 2026, highlighting continued commercial momentum for its CyPath Lung diagnostic test.
Stocks · News reference
bioAffinity Technologies Reports Record Monthly Testing Volume for CyPath Lung in October 2026
bioAffinity Technologies announced that its noninvasive lung cancer test, CyPath Lung, achieved record monthly testing volume during October 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
bioAffinity Technologies to Present CyPath Lung Test at North Carolina Healthcare Event
bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina's "Battle of the Blues" event on November 5, 2026, to discuss its CyPath Lung diagnostic test.
bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases
BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.
bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share
bioAffinity Technologies shares are trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.